Triple‐negative breast cancer (TNBC) is a highly aggressive and metastatic malignancy with
poor treatment outcomes. The interaction between the tumor microenvironment (TME) and …

Triple-negative breast cancer (TNBC) lacks estrogen receptor, progesterone receptor, and
human epidermal growth factor receptor 2 expressions, making targeted therapies …

Simple Summary Triple negative breast cancer lacks targeted therapies and has poor
prognosis; chemotherapy is currently the main treatment modality. Growing evidence has …

Abstract Triple Negative Breast Cancer (TNBC) is the most lethal subtype of breast cancer.
Despite the successes of emerging targeted therapies, relapse, recurrence, and therapy …

Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with
limited treatment options. Cancer stem cells (CSCs) are thought to play a crucial role in …

Since the discovery of breast cancer stem cells (CSCs), a significant effort has been made to
identify and characterize these cells. It is a generally believe that CSCs play an important …

Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer that lacks
targeted therapy options, and patients diagnosed with TNBC have poorer outcomes than …

Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the
absence of estrogen and progesterone receptors (ER, PR) and lacking an overexpression of …

Introduction In contrast to other breast cancer subtypes, there are currently limited options of
targeted therapies for triple-negative breast cancer (TNBC). Immense research has …

Triple-negative breast cancer (TNBC) has long been considered a major clinical challenge
due to its aggressive behavior and poor prognosis. Cancer stem cells (CSCs) are known as …